Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study - Top-Institutions - MDSpire

Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study

  • By

  • Takeshi Yasuda

  • Jun Matsubayashi

  • Hideki Ishikawa

  • Kohei Takizawa

  • July 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Kanagawa Cancer Center
    Kanagawa Cancer Center

    Kanagawa, Japan

    Key Differentiators

    • Gastroenterology

  • #2

    Jichi Medical University
    Jichi Medical University

    Tochigi, Japan

    Key Differentiators

    • Gastroenterology

  • #3

    Kobe University Hospital
    Kobe University Hospital

    Kobe, Japan

    Key Differentiators

    • Gastroenterology

  • #4

    First Affiliated Hospital of Zhejiang Chinese Medical University
    First Affiliated Hospital of Zhejiang Chinese Medical University

    Hangzhou, China

    Key Differentiators

    • Gastroenterology

Original Source(s)

Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study

  • by Takeshi Yasuda, Jun Matsubayashi, Hideki Ishikawa, Kohei Takizawa

  • July 1, 2026

Related Content

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min